Diagnostics Development Services for Glioma

Gliomas represent a diverse group of primary brain tumors originating from glial cells. The complexity of glioma biology necessitates advanced diagnostic approaches to enhance treatment outcomes. Alfa Cytology, as a prominent preclinical CRO, provides comprehensive diagnostic solutions that facilitate the understanding and management of gliomas.

Biomarkers Discovery

Whether you need biomarker identification, assay development, characterization or analysis to meet your specific requirements, Alfa Cytology is your first choice.

Disease-Specific Markers Discovery Services
Prognostic Biomarkers Discovery Services
Predictive Biomarkers Discovery Services

e.g.

IDH mutation
1p/19q codeletion
MAPK pathway alterations
ATRX
mMGMT
TERT-mut
High cfDNA

H3F3A
CDKN2A
EGFR amplification
lncRNA
Elevated serum YKL-40
miRNA-155 upreg.
miRNA-221 upreg.

miRNA-21 upreg.
miRNA-222 upreg.
miRNA-15b upreg.
miRNA-148a upreg.
miRNA-196 upreg.
miRNA-210 upreg.

Point-of-Care Test Development

At Alfa Cytology, we provide a comprehensive staged development process for Point-of-Care (POC) technology, encompassing everything from proof-of-principle design to functional prototyping and seamless production transfer.

Beads: magnetic, Colloidal gold, fluorescent
Biological sample material: whole blood, saliva, or urine

Omics Analysis Services

Our cross-disciplinary omics services enable comprehensive tumor profiling:

Platform

Genomic
Epigenomic
Proteomic
Metabolomic
Pharmacogenomic

Key Applications

Mutation screening, CNV analysis
Methylation profiling, chromatin mapping
Signaling pathway activation studies
Tumor microenvironment characterization
Treatment resistance mechanism

FAQs

What type of diagnostic products can Alfa Cytology assist with?

Alfa Cytology assists with a diverse range of diagnostic products, including point-of-care tests, laboratory diagnostics, molecular diagnostics, and tools for biomarker discovery, catering to various needs.

How do you address regulatory challenges in novel diagnostics?

Our regulatory team provides end-to-end support including pre-submission strategy, analytical validity documentation, and post-market surveillance planning.

What collaborative models do you offer?

We facilitate both fee-for-service engagements and shared-risk development partnerships, with IP flexibility tailored to sponsor requirements.